Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
"These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease." There has been much anticipation for Eli Lilly's Surpass-CVOT readout, with investors keeping a close eye on whether the dual agonism of Mounjaro could provide a cardiometabolic advantage over already-approved GLP-1 therapies
LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
People are forking for it
doi:10.3791/56190 Reinhardt CP, Dalhberg S, Tries MA, Marcel R, Leppo JA
Gentle skin pinch
US$ 20.25
.2026-03-17-04-29-59.svg)
US$ 26.68
US$ 27.75
US$ 28.93
